



**BlueCross BlueShield  
of Illinois**

# Blue Cross and Blue Shield of Illinois Provider Manual

## HMO Scope of Benefits Section

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company,  
an Independent Licensee of the Blue Cross and Blue Shield Association

# Monoclonal Antibody Imaging

## Benefit

This diagnostic test, also known as radioimmunoscintigraphy, uses radiolabeled antibodies directed against specific tumor cell markers. The labeled antibodies are injected and the member undergoes imaging 2-7 days later. The antibodies are expected to localize in metastatic areas. This test is available only for some cancers. If the PCP determines medical necessity it is in benefit.

## Interpretation

The FDA has approved the following antibody imaging agents:

1. Indium-III capromab pendetide (Prostascint®) for imaging of pelvic lymph nodes newly diagnosed members with biopsy-proven prostate cancer, or in post-prostatectomy members in whom there is a high clinical suspicion of occult metastatic disease.
2. Indium-III Pentetreotide (Octreoscan®) for use in localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
3. Indium-III satumamab pendetide (CYT-103, OncoScint CR/OV®) for imaging of colorectal and ovarian carcinomas
4. Technetium-99m arcitumomab (IMMU-4, CEA-Scan®) for imaging of colorectal and ovarian carcinomas
5. Technetium-99m nofetumomab merpentan (Verluma®) for imaging in members who have biopsy-proven small cell lung carcinoma, but who have received no treatment.

Monoclonal antibody imaging using agents 3 or 4 may be used in treatment of members with known or suspected recurrent colorectal carcinoma:

- An elevated CEA with no evidence of disease on conventional imaging modalities, including CT scan, for whom second-look laparotomy would otherwise be performed, OR
- An isolated, potentially resectable recurrence; the detection of occult lesions would alter surgical management plans.

Monoclonal antibody imaging using agent 2 may be used for the localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors (i.e. pheochromocytoma).

This is not an all-inclusive listing.

Paid by	Professional Charges	IPA
---------	----------------------	-----